iBio to Begin Trading on the Nasdaq Stock Exchange
iBio (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, announced its approval for listing on the Nasdaq Capital Market. The company will transfer its stock exchange listing from NYSE American to Nasdaq, with trading expected to begin on March 4, 2025, maintaining its "IBIO" symbol. Trading on NYSE American will continue until market close on March 3, 2025.
CEO and Chief Scientific Officer Martin Brenner expressed optimism about joining the Nasdaq community of biotech companies, anticipating improved stock visibility, enhanced trading liquidity, and greater exposure to institutional investors.
iBio (NYSEA:IBIO), un innovatore nel campo delle terapie con anticorpi di precisione guidato dall'IA, ha annunciato l'approvazione per la quotazione sul Nasdaq Capital Market. L'azienda trasferirà la sua quotazione da NYSE American a Nasdaq, con l'inizio delle negoziazioni previsto per il 4 marzo 2025, mantenendo il simbolo "IBIO". Le negoziazioni su NYSE American continueranno fino alla chiusura del mercato il 3 marzo 2025.
Il CEO e Chief Scientific Officer Martin Brenner ha espresso ottimismo riguardo all'ingresso nella comunità Nasdaq delle aziende biotecnologiche, prevedendo una maggiore visibilità delle azioni, una liquidità di trading migliorata e una maggiore esposizione agli investitori istituzionali.
iBio (NYSEA:IBIO), un innovador impulsado por IA en terapias de anticuerpos de precisión, anunció su aprobación para la cotización en el Nasdaq Capital Market. La empresa transferirá su cotización de NYSE American a Nasdaq, con el inicio de las operaciones previsto para el 4 de marzo de 2025, manteniendo su símbolo "IBIO". Las operaciones en NYSE American continuarán hasta el cierre del mercado el 3 de marzo de 2025.
El CEO y Director Científico Martin Brenner expresó optimismo sobre unirse a la comunidad Nasdaq de empresas biotecnológicas, anticipando una mejor visibilidad de las acciones, una mayor liquidez de negociación y una mayor exposición a los inversores institucionales.
iBio (NYSEA:IBIO)는 AI 기반의 정밀 항체 치료 혁신 기업으로서 Nasdaq Capital Market 상장 승인을 발표했습니다. 회사는 NYSE American에서 Nasdaq으로 주식 상장을 이전하며, 거래는 2025년 3월 4일에 시작될 예정이며, "IBIO" 기호는 유지됩니다. NYSE American에서의 거래는 2025년 3월 3일 시장 종료 시까지 계속됩니다.
CEO이자 최고 과학 책임자인 마틴 브레너는 바이오텍 기업의 Nasdaq 커뮤니티에 합류하게 되어 낙관적이라는 입장을 밝혔으며, 주식 가시성 향상, 거래 유동성 개선 및 기관 투자자들에게의 노출 증가를 기대하고 있습니다.
iBio (NYSEA:IBIO), un innovateur guidé par l'IA dans le domaine des thérapies par anticorps de précision, a annoncé son approbation pour une cotation sur le Nasdaq Capital Market. L'entreprise transférera sa cotation de NYSE American vers le Nasdaq, avec un début des transactions prévu pour le 4 mars 2025, tout en maintenant son symbole "IBIO". Les transactions sur NYSE American se poursuivront jusqu'à la fermeture du marché le 3 mars 2025.
Le PDG et directeur scientifique Martin Brenner a exprimé son optimisme quant à l'entrée dans la communauté Nasdaq des entreprises biotechnologiques, anticipant une meilleure visibilité des actions, une liquidité de négociation accrue et une plus grande exposition aux investisseurs institutionnels.
iBio (NYSEA:IBIO), ein von KI gesteuertes Unternehmen für präzise Antikörpertherapien, hat die Genehmigung für die Notierung am Nasdaq Capital Market erhalten. Das Unternehmen wird seine Börsennotierung von NYSE American auf Nasdaq übertragen, wobei der Handel voraussichtlich am 4. März 2025 beginnen wird, während das Symbol "IBIO" beibehalten wird. Der Handel an der NYSE American wird bis zum Marktschluss am 3. März 2025 fortgesetzt.
CEO und Chief Scientific Officer Martin Brenner äußerte Optimismus über den Beitritt zur Nasdaq-Community der Biotech-Unternehmen und erwartet eine verbesserte Sichtbarkeit der Aktien, eine erhöhte Handelsliquidität und eine größere Exposition gegenüber institutionellen Investoren.
- Nasdaq listing approval secured, potentially increasing institutional investor exposure
- Expected enhanced trading liquidity for shareholders
- Maintained trading symbol consistency (IBIO) during exchange transition
- None.
Insights
This move is particularly strategic for iBio as a biotech company, as Nasdaq hosts approximately 98% of publicly traded biotech companies. This concentration creates a more focused ecosystem where sector-specific analysts, institutional investors, and market makers are already actively engaged. The enhanced visibility could lead to increased coverage from biotech-focused research analysts and potentially improve inclusion in sector-specific ETFs and indexes.
The timing of the transition during a period of significant AI-driven innovation in the biotech sector could amplify the benefits. Nasdaq's sophisticated market structure and technology infrastructure are particularly well-suited for companies with complex valuation metrics typical in the biotech sector. The platform's advanced trading algorithms and market-making systems could help optimize price discovery and reduce volatility.
However, investors should note that exchange transitions can temporarily affect trading patterns as market makers adjust their systems and algorithmic trading programs recalibrate. The key period to watch will be the first few weeks post-transition, as new market makers establish positions and trading patterns normalize.
From a corporate perspective, this move aligns with iBio's positioning as an AI-driven innovator in precision antibody therapies. Nasdaq's association with technology and innovation could help reinforce this market perception and potentially attract investors who specifically target companies at the intersection of biotech and AI. The exchange's enhanced visibility tools and corporate services could also support iBio's investor relations efforts and capital markets strategy.
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol “IBIO.” The Company’s common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025.
Martin Brenner, Ph.D., DVM, iBio’s CEO and Chief Scientific Officer, commented, “We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotech companies. We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”
About iBio, Inc.
iBio (NYSEA: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the transfer to Nasdaq, anticipated date of commencement of trading on the Nasdaq and continuation of trading on the NYSE American and the move to Nasdaq improving the visibility of the Company’s common stock, enhancing trading liquidity in the shares, and providing the Company with greater exposure to institutional investors. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to derive the anticipated benefits from the move to Nasdaq, the Company’s ability to execute its growth strategy and advance its pipeline of therapeutic antibody candidates for cardiometabolic diseases and oncology; the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether the Company will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in the Company’s filings with the SEC including the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
When will IBIO start trading on Nasdaq?
Will IBIO change its stock symbol after moving to Nasdaq?
When will IBIO stop trading on NYSE American?
What benefits does the Nasdaq listing bring to IBIO?
